Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794845 · ClinicalTrials.gov registry record · Phase 2
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
A Phase 2 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01794845 is a Phase 2 study that was terminated before completion, run by University of Miami. The registered enrollment target is 5 participants.
The verdict
NCT01794845, a Phase 2 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
Interventions
- DRUG Taxotere
- DRUG Erbitux
- RADIATION Low Dose Fractionated Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-06-03 |
| Est. Completion | 2016-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794845
The ClinicalTrials.gov registry entry for NCT01794845 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Taxotere is the first listed.
NCT01794845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794845 about?
NCT01794845 is a clinical study titled "Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma". Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
What is the current status of trial NCT01794845?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-06-03. Estimated completion is 2016-06-07.
What interventions are being tested in trial NCT01794845?
The interventions under investigation include: Taxotere (DRUG), Erbitux (DRUG), Low Dose Fractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01794845?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.